Key facts
- It has raised $14.0M; the latest was Early Stage VC in Jan 2026.
- Notable investors include Qiming Venture Partners, B Capital Group, Shun Xi Fund, Hankang Capital, C&D Emerging Investment — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Microwave Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Microwave Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Microwave Bio
Developer of targeted therapeutic technologies intended for treatment outcomes for hematological malignancies and autoimmune disorders. The company offers an in vivo approach leveraging lipid nanoparticle delivery systems and proprietary algorithms to enable direct CAR expression within patient T cells, eliminating complex pre-treatment steps and reducing toxicity, enabling healthcare providers to shorten therapy cycles and enhance accessibility for advanced cell-based treatments.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Microwave Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Microwave Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Microwave Bio in its N-PORT filings yet. We sweep new filings monthly.